pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Radioligand Therapy · news · pharmadog
← back to Radioligand Therapy
News · Radioligand Therapy
144
stories
5d
PharmaLogic buys Lantheus plant to build transatlantic radiopharmaceutical CDMO
biospace
6d
Chutes & Ladders—Bristol Myers' research chief out amid R&D reorganization
fiercebiotech
11d
Could we see 10 Chinese Big Pharmas within a decade? Some CEOs think so
fiercebiotech
20d
Molecular Partners to lay off up to 44% of workforce in radiotherapy pivot
fiercebiotech
20d
BMS drops Prothena-partnered neuro drug, sales outlook improves on a Q3 beat
biospace
23d
ESMO 2026: J&J delivers ‘immaculate’ early data for prostate cancer drug from Halda
biospace
Oct 12, 26
Bristol Myers dips on ‘confounding’ lung drug results
biopharma dive
Oct 12, 26
BMS’ Phase 3 win for lung drug clouded by high-dose miss
biospace
Oct 12, 26
BMS’ $4.1B RayzeBio bet delivers Phase 3 radiopharma win
biospace
Oct 12, 26
BMS doubles up with pivotal wins in lung disease, solid tumor that offer hope for post-patent cliff growth
fiercebiotech
Oct 6, 26
GE HealthCare to acquire Sofie Biosciences for $945M
biopharma dive
Sep 29, 26
3 steps for taking on Novartis in radiopharma: Curium up first
biospace
Sep 24, 26
How radioligand therapy is rewriting cancer care
biospace
Sep 23, 26
Novartis bets up to $900M for radioligand therapy from China’s BoomRay
biospace
Sep 22, 26
Amgen's Phase 3 Sjögren's win; Novartis' $900M radioligand deal
endpoints
Sep 22, 26
Novartis secures new radioligand in $900M deal as competition strengthens
fiercebiotech
Sep 21, 26
Western licensing deals for Chinese radioligand therapies to jump in 2027, Sleuth forecasts
biospace
Sep 21, 26
Sleuth forecasts 2027 jump in Western license deals for Chinese radioligand therapies
biospace
Sep 21, 26
Telix buys ITM for $1.65B in ‘supercritical’ radiopharma M&A
biospace
Sep 21, 26
Telix buys ITM in bid to create a ‘radiopharmaceutical powerhouse’
biopharma dive
Sep 21, 26
Analysts ‘extremely bullish’ as Telix beams into Novartis’ territory with $1.6B ITM acquisition
fiercebiotech
Sep 20, 26
STAT+: Radiopharma companies merge after one receives surprise FDA rejection
stat
Sep 15, 26
FDA clears first generic radioligand drug; Sionna turns to layoffs
biopharma dive
Sep 15, 26
FDA approves first radioligand generic, setting up rivalry with Novartis
endpoints
Sep 13, 26
GE HealthCare mulls $1B imaging chemicals maker deal: Financial Times
fiercebiotech
Sep 11, 26
Novartis’ board faces investor scrutiny after M&A misfires and R&D flops
biospace
Sep 10, 26
Chutes & Ladders—Longtime Takeda R&D chief to depart next June
fiercebiotech
Aug 31, 26
STAT+: Cadre of radiopharmaceuticals experts pushes the bounds in cancer therapy
stat
Aug 25, 26
Preparing for Novartis showdown, Curium touts value of radiopharma supply resiliency
biospace
Aug 18, 26
Regeneron ends eye disease study due to antibody's safety profile
biospace
← prev
page 1 of 5
next →